Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927778 | 1.00 | FFAR1 (0.43) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL18940276 | 1.00 | FFAR1 (0.43) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL19669155 | 0.93 | ROCK1 (0.38) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL16845952 | 0.90 | FFAR1 (0.38) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL29423910 | 0.90 | FFAR1 (0.38) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL29423898 | 0.90 | FFAR1 (0.38) | FFAR1ROCK1SCN3AHIF1ABACE1 | |
| SCHEMBL18940305 | 0.85 | FFAR1 (0.44) | FFAR1HIF1ADGAT1 | |
| SCHEMBL18940280 | 0.85 | FFAR1 (0.44) | FFAR1HIF1ADGAT1 | |
| SCHEMBL18940277 | 0.83 | FFAR1 (0.42) | FFAR1SCN3A | |
| SCHEMBL18940292 | 0.82 | FFAR1 (0.35) | FFAR1ROCK1HIF1ABACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082786-B1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | GPR119, GPR65, GPR55 | FFAR1 13/4885ROCK1 3440/4885SCN3A 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.